ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

The treatment, now available in England, targets myeloma, a blood cancer affecting plasma cells in the bone marrow. It ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...

New research presented by Noella Collado-Gisbert reveals that tracking residual disease kinetics in multiple myeloma predicts ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma Recommendation based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd ...

Multiple myeloma accounts for 15 per cent of all blood cancers and in recent years, its prevalence has risen sharply and is ...